

# Caris Life Sciences' Molecular Intelligence Reports Optimized for the American Society of Clinical Oncology, Inc. TAPUR Study

Caris Molecular Intelligence Tumor Profiling Reports Optimized to Molecularly Identify Genomic Alterations for the TAPUR Study

For immediate release

June 8, 2017

## **ASCO Contact:**

Kate Crawford

571-483-1366

[Kate.Crawford@asco.org](mailto:Kate.Crawford@asco.org)

## **The Ruth Group Contact:**

Kirsten Thomas / Joanna Zimmerman

[ktthomas@theruthgroup.com](mailto:ktthomas@theruthgroup.com) / [jzimmerman@theruthgroup.com](mailto:jzimmerman@theruthgroup.com)

Tel: +1-508-280-6592 / +1-646-536-7006

## **Caris Life Sciences Contact:**

[CorpComm@carisls.com](mailto:CorpComm@carisls.com)

214-294-5606

IRVING, Texas— Caris Life Sciences<sup>®</sup>, a leading innovator in molecular science, and the American Society of Clinical Oncology, Inc. (ASCO<sup>®</sup>), today announced that Caris is one of the first laboratories to have a test report optimized for ASCO's Targeted Agent and Profiling Utilization Registry (TAPUR<sup>™</sup>) Study. The TAPUR Study is evaluating efficacy of treatments based on patients' tumor genetic profiles. This designation indicates that the company's proprietary Caris Molecular Intelligence<sup>®</sup> comprehensive genomic profiling *plus* (CGP+) tumor profiling platform report is optimized to molecularly identify and report genomic alterations specifically for the TAPUR Study.

Caris Molecular Intelligence, which has performed more than 117,000 clinical cases to date and helps physicians and researchers more effectively evaluate therapy options and clinical trial opportunities, meets the TAPUR Study's established requirements for optimized reporting. The Caris reports include specific genomic results and simplified data entry by way of an addendum

report specifically for TAPUR Study participating centers in a format approved by the ASCO TAPUR Study team. TAPUR sites ordering these tests will be able to easily identify relevant TAPUR variants on a specialized report for potential participants.

“ASCO’s TAPUR Study represents a massive and concerted effort by multiple collaborators and more than 100 clinical sites across 20 states as a ground-breaking trial uniquely focused on learning from the use of 15 approved targeted cancer therapies matched to tumor genomics for an effective precision medicine strategy,” said John Marshall, MD, Chief Medical Officer of Caris Life Sciences. Dr. Marshall is also the Associate Director for Clinical Care for the Georgetown Lombardi Comprehensive Cancer Center and the Chief of the Division of Hematology-Oncology at MedStar Georgetown University Hospital in Washington, D.C. “We are excited to participate by providing optimized Caris Molecular Intelligence test reports that effectively inform clinicians on patients’ tumor profiles at the TAPUR Study centers to guide more precise and individualized patient treatment decisions, and we look forward to furthering the success of this significant trial.”

“We are excited to work with Caris Life Sciences on the TAPUR Study,” said Richard L. Schilsky, MD, FACP, FASCO, TAPUR study principal investigator. “TAPUR is designed to identify signals of drug activity for targeted anti-cancer drugs used outside of their approved indications. The optimized Caris test report will help TAPUR clinical sites determine who is eligible in a much more expedient fashion.”

The TAPUR Study is a non-randomized clinical trial that aims to describe the performance, including both safety and efficacy, of commercially available, targeted anti-cancer drugs prescribed for treatment of patients with advanced cancer based on prospectively-defined and potentially actionable genomic variants. The study provides approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies, catalogues the choice of genomic profiling test by clinical oncologists and aims to learn about the utility of registry data to develop hypotheses for additional clinical trials.

## **About ASCO:**

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at [www.ASCO.org](http://www.ASCO.org), explore patient education resources at [www.Cancer.Net](http://www.Cancer.Net), and follow us

on Facebook, Twitter, LinkedIn, and YouTube.

## **About Caris Life Sciences<sup>®</sup>**

Caris Life Sciences<sup>®</sup> is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. Caris Molecular Intelligence<sup>®</sup>, the company's Comprehensive Genomic Profiling Plus (CGP+) molecular testing service and the world's leading immunotherapy diagnostic expert, assesses DNA, RNA and proteins, including microsatellite instability (MSI), total mutational load (TML) and PD-L1, to reveal a molecular blueprint to guide more precise and personalized treatment decisions. The ADAPT Biotargeting System<sup>™</sup>, the company's revolutionary and unbiased profiling platform, is currently being utilized for drug target identification, therapeutic discovery and development, fixed tissue-based companion diagnostics, blood-based cancer screening and biomarker identification. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe and other international markets. To learn more, please visit [www.CarisLifeSciences.com](http://www.CarisLifeSciences.com).

---